Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
We are developing a topical formulation of minocycline utilizing our proprietary foam technology platform. Our development program consists of three potential indications that we are pursuing: moderate-to-severe acne, impetigo, and rosacea.
Our phase II results of minocycline foam 4%, applied once-daily, for the treatment of moderate-to-severe acne, showed greater than a 70% reduction in inflammatory acne lesions. We intend to commence Phase III trials for minocycline foam 4% in the United States in 2016
Foamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals